The sweet side of tumor immunotherapy

Immunotherapy

Volumn 4, Issue 7, 2012, Pages 719-734

  Freire, Teresa ^a,b   Osinaga, Eduardo ^a,b  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

Author keywords

cancer; glycosylation; immunotherapy; tumor associated carbohydrate antigen; vaccine

Indexed keywords

CARBOHYDRATE; CARBOHYDRATE ANTIGEN; GLYCAN;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXICITY; GLYCOSYLATION; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84864597970     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.58     Document Type: Review

References (166)

1. Ono M, Hakomori S. Glycosylation defning cancer cell motility and invasiveness. Glycoconj. J. 20(1), 71-78 (2004).
2. Newton K, Dixit V. Signaling in innate immunity and infammation. Cold Spring Harb. Perspect. Biol. 4(3), a006049 (2012).
3. Petersen J, Purcell A, Rossjohn J. Post-translationally modifed T cell epitopes: immune recognition and immunotherapy. J. Mol. Med. (Berl.). 87(11), 1045-1051 (2009).
4. Rambaruth N, Dwek M. Cell surface glycan-interactions in tumor melectin tastasis. Acta Histochem. 113(6), 591-600 (2011).
5. Freire T, Bay S, Vichier-Guerre S, Lo-Man R, Leclerc C. Carbohydrate antigens: synthesis aspects and immunological applications in cancer. Mini Rev. Med. Chem. 6(12), 1357-1373 (2006).
6. Granovsky M, Fata J, Pawling J et al. Suppression of tumor growth and metastasis in Mgat5-defcient mice. Nat. Med. 6, 306-312 (2000).
7. Bos P, Zhang X, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
8. Matsumoto Y, Zhang Q, Akita K et al. pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen. Biochem. Biophys. Res. Commun. 419, 7-13 (2012).
9. Lau K, Dennis J. N-Glycans in cancer progression. Glycobiology 18(10), 750-760 (2008).
10. Kim Y, Yuan M, Itzkowitz S et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res. 46(11), 5985-5992 (1986).
11. Sakamoto S, Watanabe T, Tokumaru T et al. Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res. 49(3), 745-752 (1989).
12. Tanaka F, Miyahara R, Ohtake Y et al. Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann. Thorac. Surg. 66(5), 1745-1750 (1998).
13. Yin BW, Finstad C, Kitamura K et al. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int. J. Cancer. 65(4), 406-412 (1996).
14. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22(42), 6524-6536 (2003).
15. Suzuki O, Nozawa Y, Abe M. The regulatory roles of cell surface sialylation and N-glycans in human B cell lymphoma cell adhesion to galectin-1. Int. J. Oncol. 28(1), 155-160 (2006).
16. Brockhausen I. Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Adv. Exp. Med. Biol. 535, 163-188 (2003).
17. Hakomori S. Tumor-associated carbohydrate antigens defning tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001).
18. Itzkowitz S, Bloom E, Kokal W et al. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66(9), 1960-1966 (1990).
19. Itzkowitz S, Yuan M, Montgomery C et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 49(1), 197-204 (1989).
20. Langkilde N, Wolf H, Clausen H, Kjeldsen T, Orntoft T Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression. Cancer 69(1), 219-227 (1992).
21. Langkilde N, Wolf H, Clausen H, Orntoft TF. Localization and identifcation of T-(Gal beta 1-3GalNAc alpha 1-O-R) and T-like antigens in experimental rat bladder cancer. J. Urol. 148(4), 1279-1284 (1992).
22. Muramatsu T Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology 3(4), 291-296 (1993).
23. Cao Y, Stosiek P, Springer G, Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study Histochem. Cell Biol. 106(2), 197-207 (1996).
24. Springer G. T and Tn, general carcinoma autoantigens. Science 224(4654), 1198-1206 (1984).
25. Fuster M, Esko J. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5(7), 526-542 (2005).
26. Nores G, Dohi T, Taniguchi M, Hakomori S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol. 139(9), 3171-3176 (1987).
27. Birks S, Danquah J, King L et al. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro. Oncol. 13(9), 950-960 (2011).
28. Brezicka F, Olling S, Nilsson O et al. Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 49(5), 1300-1305 (1989).
29. Nilsson O, Brezicka F, Holmgren J et al. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Cancer Res. 46(3), 1403-1407 (1986).
30. Vangsted A, Clausen H, Kjeldsen T et al. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1 antigen in serum. Cancer Res. 51(11), 2879-2884 (1991).
31. Zhang S, Zhang H, Reuter V et al. Expressio of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4(2), 295-302 (1998).
32. Li M, Song L, Qin X. Glycan changes: cance metastasis and anti-cancer vaccines. J. Biosci. 35(4), 665-673 (2010).
33. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
34. Vesely M, Kershaw M, Schreiber R, Smyth M. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 235-271 (2011).
35. Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
36. Ostrand-Rosenberg S, Sinha P, Beury D, Clements V. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. (2012).
37. Fridman W, Mlecnik B, Bindea G, Pagès F, Galon J. Immunosurveillance in human non-viral cancers. Curr. Opin. Immunol. 23(2), 272-278 (2011).
38. Quezada S, Peggs K, Simpson T, Allison J. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241(1), 104-118 (2011).
39. Wesseling J, Van Der Valk S, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell. 7(4), 565-577 (1996).
40. Glinsky V, Glinsky G, Glinskii O et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 63(13), 3805-3811 (2003).
41. Pinho S, Marcos N, Ferreira B et al. Biological signifcance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 249(2), 157-170 (2007).
42. Carlos C, Dong H, Howard O et al. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity J. Immunol. 175(3), 1628-1635 (2005).
43. Yokoigawa N, Takeuchi N, Toda M et al. Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. Cancer Lett. 245(1-2), 149-155 (2007).
44. Sugihara I, Yoshida M, Shigenobu T et al. Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice. Cancer Res. 66(12), 6175-6182 (2006).
45. Varki A. Selectin ligands: will the real ones please stand up? J. Clin. Invest. 99(2), 158-162 (1997).
46. Portela S, Martín C, Romay L et al. sLea and sLex expression in colorectal cancer: implications for tumourigenesis and disease prognosis. Histol. Histopathol. 26(10), 1305-1316 (2011).
47. Cazet A, Julien S, Bobowski M et al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res. 345(10), 1377-1383 (2010).
48. Julien S, Ivetic A, Grigoriadis A et al. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 71(24), 7683-7693 (2011).
49. Zou J, Glinsky V, Landon L, Matthews L, Deutscher S. Peptides specifc to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26(2), 309-318 (2005).
50. Almogren A, Abdullah J, Ghapure K et al. Anti-Thomsen-Frieden reich-Ag (anti-TF-Ag) potential for cancer therapy. Front. Biosci. (Schol. Ed.). 4, 840-863 (2012).
51. Nangia-Makker P, Hogan V, Honjo Y et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modifed citrus pectin. J. Natl Cancer Inst. 94, 1854-1862 (2002).
52. Glinsky V, Raz A. Modifed citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr. Res. 344, 1788-1791 (2009).
53. Glinskii O, Huxley V, Glinsky G et al. Mechanical entrapment is insuffcient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7, 522-527 (2005).
54. Shurin G, Shurin M, Bykovskaia S et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61(1), 363-369 (2001).
55. Biswas K, Richmond A, Rayman P et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 66(13), 6816-6825 (2006).
56. Ryan S, Turner M, Gariépy J, Finn O. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 70(14), 5788-5796 (2010).
57. Lindenberg J, Fehres C, Van Cruijsen H, Oosterhoff D, De Gruijl T Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity Immunotherapy 3, 77-96 (2011).
58. Freire T, Lo-Man R, Bay S, Leclerc C. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J. Biol. Chem. 286(10), 7797-7811 (2011).
59. Haurum J, Arsequell G, Lellouch A et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specifc cytotoxic T lymphocytes. J. Exp. Med. 180(2), 739-744 (1994).
60. Corthay A, Bäcklund J, Broddefalk J et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur. J. Immunol. 28(8), 2580-2590 (1998).
61. Ninkovic T, Hanisch F. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J. Immunol. 179(4), 2380-2388 (2007).
62. Hanisch F, Schwientek T, Von Bergwelt-Baildon M, Schultze J, Finn O. O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur. J. Immunol. 33(12), 3242-3254 (2003).
63. Hiltbold E, Vlad A, Ciborowski P, Watkins S, Finn O. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165(7), 3730-3741 (2000).
64. Turner M, Cohen P, Finn O. Lack of effective MUC1 tumor antigen-specifc immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178(5), 2787-2793 (2007).
65. Bennaceur K, Popa I, Chapman J et al. Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells. Glycobiology 19(6), 576-582 (2009).
66. Hossain D, Mohanty S, Ray P, Das T, Sa G. Tumor gangliosides and T cells: a deadly encounter. Front. Biosci. (Schol. Ed.). 4, 502-519 (2012).
67. Shinkai Y, Rathbun G, Lam K et al. Rag-2-defcient mice lack mature lymphocytes owing to inability to initiate V (D) J rearrangement. Cell 68, 855-867 (1992).
68. Carbone F, Gleeson P. Carbohydrates and antigen recognition by T cells. Glycobiology 7(6), 725-730 (1997).
69. Cloos P, Christgau S. Post-translational modifcations of proteins: implications for aging, antigen recognition, and autoimmunity. Biogerontology 5(3), 139-158 (2004).
70. Urban E, Chapoval A, Pauza C. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin. Dev. Immunol. 2010, 732893 (2010).
71. Godfrey D, Pellicci D, Patel O et al. Antigen recognition by CD 1d-restricted NKT T cell receptors. Semin. Immunol. 22(2), 61-67 (2010).
72. Venkataswamy M, Porcelli S. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. 22(2), 68-78 (2010).
73. Dhodapkar M. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Frontiers Biosc. 14, 796-807 (2009).
74. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
75. Van Kooyk Y, Rabinovich G. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 9(6), 593-601 (2008).
76. Pashov A, Monzavi-Karbassi B, Raghava G, Kieber-Emmons T Bridging innate and adaptive antitumor immunity targeting glycans. J. Biomed. Biotechnol. 2010, 354068 (2010).
77. Crocker P, Varki A. Siglecs in the immune system. Immunology 103(2), 137-145 (2001).
78. O'reilly M, Paulson J. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30(5), 240-248 (2009).
79. Ikehara Y, Ikehara S, Paulson J. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J. Biol. Chem. 279(41), 43117-43125 (2004).
80. Swanson B, Mcdermott K, Singh P et al. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67(21), 10222-10229 (2007).
81. Belisle J, Horibata S, Jennifer G et al. Identifcation of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer. 9(118) (2010).
82. Freire T, Zhang X, Dériaud E et al. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood 116(18), 3526-3536 (2010).
83. Mcgreal E, Miller J, Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin Immunol. 17(1), 18-24 (2005).
84. Sancho D, Reis E, Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30, 491-529 (2011).
85. Saeland E, Van Vliet S, Bäckström M et al. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol. Immunother. 56(8), 1225-1236 (2007).
86. Van Vliet S, Saeland E, Van Kooyk Y. Sweet preferences of MGL: carbohydrate specifcity and function. Trends Immunol. 29(2), 83-90 (2008).
87. Zhao X, Cheung N. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J. Exp. Med. 182(1), 67-74 (1995).
88. Forestier C, Moreno E, Méresse S et al. Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes. Inf. Immunity 67(8), 4048-4054 (1999).
89. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222(129), 44 (2008).
90. Galli-Stampino L, Meinjohanns E, Frische K et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. 57(15), 3214-3222 (1997).
91. Jensen T, Galli-Stampino L, Mouritsen S et al. T cell recognition of Tn-glycosylated peptide antigens. Eur. J. Immunol. 26(6), 1342-1349 (1996).
92. Vlad A, Muller S, Cudic M et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196(11), 1435-1446 (2002).
93. Abdel-Motal UM, Berg L, Rosen A et al. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specifc, unrestricted cytotoxic T cells. Eur. J. Immunol. 26(3), 544-551 (1996).
94. Xu Y, Gendler S, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 199(5), 707-716 (2004).
95. Apostolopoulos V, Yuriev E, Ramsland P et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl Acad. Sci. USA 100(25), 15029-15034 (2003).
96. Springer G, Desai P. Tn epitopes, immunoreactive with ordinary anti-Tn antibodies, on normal, desialylated human erythrocytes and on Thomsen-Friedenreich antigen isolated therefrom. Mol. Immunol. 22(11), 1303-1310 (1985).
97. Kurtenkov O, Miljukhina L, Smorodin J et al. Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors-relation to Lewis (a,b) histo-blood group phenotype. Acta Oncol. 38(7), 939-943 (1999).
98. Livingston P, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12(14), 1275-1280 (1994).
99. Livingston P, Wong G, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994).
100. Wandall H, Blixt O, Tarp M et al. Cancer biomarkers defned by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 70(4), 1306-1313 (2010).
101. Schietinger A, Philip M, Yoshida B et al. A mutant chaperone converts a wild-type protein into a tumor-specifc antigen. Science 314(5797), 304-308 (2006).
102. Galili U, Latemple D. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol. Today 18(6), 281-285 (1997).
103. Ragupathi G, Liu NX, Musselli C et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 174(9), 5706-5712 (2005).
104. Hubert P, Heitzmann A, Viel S et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specifc antibody immunotherapy. Cancer Res. 71(15), 5134-5143 (2011).
105. Mayer P, Handgretinger R, Bruchelt G et al. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14. G2a. Melanoma Res. 4(2), 101-106 (1994).
106. Durrant L, Pudney V, Spendlove I. Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev. Vaccines 10(7), 1093-1106 (2011).
107. Kirkwood J, Mascari R, Edington H et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 88(12), 2693-2702 (2000).
108. Retter M, Johnson J, Peckham D et al. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res. 65(14), 6425-6434 (2005).
109. Alvarez-Rueda N, Leprieur S, Clémenceau B et al. Binding activities and antitumor properties of a new mouse/human chimeric antibody specifc for GD2 ganglioside antigen. Clin. Cancer Res. 13(18), S5613-S5620 (2007).
110. Kitamura K, Stockert E, Garin-Chesa P et al. Specifcity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. Proc. Natl Acad. Sci. USA. 91(26), 12957-12961 (1994).
111. Sawada R, Sun S, Wu X et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin. Cancer Res. 17(5), 1024-1032 (2011).
112. Durrant L, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin. Exp. Immunol. 167(2), 206-215 (2012).
113. Gubbels J, Gadbaw B, Buhtoiarov I et al. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol. Immunother. 60(12), 1789-1800 (2011).
114. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45 (2003).
115. Ramos C, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol. Ther. 11(7), 855-873 (2011).
116. Rossig C, Bollard C, Nuchtern J, Merchant D, Brenner M. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer. 94, 228-236 (2001).
117. Yun C, Nolan K, Beecham E, Reisfeld R, Junghans R. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2, 449-459 (2000).
118. Yvon E, Del Vecchio M, Savoldo B et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specifc T cells. Clin. Cancer Res. 15, 5852-5860 (2009).
119. Lo A, Ma Q, Liu D, Junghans R. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16(10), 2769-2780 (2010).
120. Westwood J, Smyth M, Teng M et al. Adoptive transfer of T cells modifed with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl Acad. Sci. USA 102, 19051-19056 (2005).
121. Wilkie S, Picco G, Foster J et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901-4909 (2008).
122. Maher J, Wilkie S. CAR mechanics: driving T cells into the MUC of cancer. Cancer Res. 69, 4559-4562 (2009).
123. Wilkie S, Burbridge S, Chiapero-Stanke L et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538-25544 (2010).
124. Cartellieri M, Bachmann M, Feldmann A et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 956304 (2010).
125. Helling F, Livingston P. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol. Chem. Neuropathol. 21(2-3), 299-309 (1994).
126. Kagan E, Ragupathi G, Yi S et al. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54(5), 424-430 (2005).
127. Kudryashov V, Kim H, Ragupathi G et al. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines. Cancer Immunol. Immunother. 45(6), 281-286 (1998).
128. Guo Z, Wang Q. Recent development in carbohydrate-based cancer vaccines. Curr. Opin Chem. Biol. 13(5-6), 608-617 (2009).
129. Bay S, Fort S, Birikaki L et al. Induction of a melanoma-specifc antibody response by a monovalent, but not a divalent, synthetic GM2 neoglycopeptide. Chem. Med. Chem. 4(4), 582-587 (2009).
130. Fung P, Madej M, Koganty R, Longenecker B. Active specifc immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 50(14), 4308-4314 (1990).
131. Grigalevicius S, Chierici S, Renaudet O et al. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered tn antigen as synthetic anticancer vaccines. Bioconjug. Chem. 16(5), 1149-1159 (2005).
132. Kudryashov V, Glunz P, Williams L et al. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all infuence antibody responses to Lewis(y) conjugates in mice. Proc. Natl Acad. Sci. USA 98(6), 3264-3269 (2001).
133. Lo-Man R, Vichier-Guerre S, Dériaud E et al. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide (MAG) displaying a tri-Tn glycotope. J. Immunol. 166, 2849-2854 (2001).
134. Lo-Man R, Vichier-Guerre S, Perraut R et al. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specifc antibodies in nonhuman primates. Cancer Res. 64(14), 4987-4994 (2004).
135. Longenecker B, Reddish M, Koganty R, Maclean G. Immune responses of mice and human breast cancer patients following immunization with synthetic Sialyl-Tn conjugated to KLH plus Detox adjuvant. Ann. NY Acad. Sci. 690, 276-291 (1993).
136. Longenecker B, Reddish M, Koganty R, Maclean G. Specifcity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional signifcance in metastasis. Adv. Exp. Med. Biol. 353, 105-124 (1994).
137. Ragupathi G, Cappello S, Yi S et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20(7-8), 1030-1038. (2002).
138. Toyokuni T, Hakomori S, Singhal A. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg. Med. Chem. 2(11), 1119-1132 (1994).
139. Chapman P, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10(14), 4717-4723. (2004).
140. Maclean G, Reddish M, Koganty R et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 36(4), 215-222 (1993).
141. Slovin S, Keding S, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83(4), 418-428 (2005).
142. Vichier-Guerre S, Lo-Man R, Bay S et al. Short synthetic glycopeptides successfully induce antibody responses to carcinoma-associated Tn antigen. J. Pept. Res. 55(2), 173-180 (2000).
143. Osinaga E, Bay S, Tello D et al. Analysis of the fne specifcity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectroscopy. FEBS Lett. 469(1), 24-28 (2000).
144. Karsten U, Diotel C, Klich G et al. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specifc glycosylation. Cancer Res. 58(12), 2541-2549 (1998).
145. Karsten U, Von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour Biol. 26(4), 217-220 (2005).
146. Von Mensdorff-Pouilly S, Petrakou E, Kenemans P et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer. 86(5), 702-712 (2000).
147. Grinstead J, Schuman J, Campbell A. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study. Biochemistry 42(48), 14293-14305 (2003).
148. Von Mensdorff-Pouilly S, Kinarsky L, Engelmann K et al. Sequence-variant repeats of MUC1 show higher conformational fexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 15(8), 735-746 (2005).
149. Ryan S, Vlad A, Islam K, Gariépy J, Finn O. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol. Chem. 390(7), 611-618 (2009).
150. Zhu J, Wan Q, Lee D et al. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. J. Am. Chem. Soc. 131(26), 9298-9303 (2009).
151. Tarp M, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta. 1780(3), 546-563 (2008).
152. Corzana F, Busto J, García De Luis M et al. The nature and sequence of the amino acid aglycone strongly modulates the conformation and dynamics effects of Tn antigen's clusters. Chemistry 15(15), 3863-3874 (2009).
153. Ragupathi G, Livingston P, Hood C et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9, 5214-5220 (2003).
154. Pan Y, Chefalo P, Nagy N, Harding C, Guo Z. Synthesis and immunological properties of N-modifed GM3 antigens as therapeutic cancer vaccines. J. Med. Chem. 48, 875-883 (2005).
155. Chefalo P, Pan Y, Nagy N, Guo Z, Harding C V. Effcient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine. Biochemistry 45(11), 3733-3739 (2006).
156. Liu D, Song D, Guo G et al. The synthesis of 18beta-glycyrrhetinic acid derivatives which have increased antiproliferative and apoptotic effects in leukemia cells. Bioorg. Med. Chem. 15(16), 5432-5439 (2007).
157. Dudziak D, Kamphorst A, Heidkamp G et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315(5808), 107-111 (2007).
158. Klechevsky E, Morita R, Liu M et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29(3), 497-510 (2008).
159. Geijtenbeek T, Gringhuis S. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9(7), 465-479 (2009).
160. Singh S, Streng-Ouwehand I, Litjens M et al. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur. J. Immunol. 41(4), 916-925 (2011).
161. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: infuence of cyclophosphamide and the route of injection. J. Immunother. 24(2), 172-183 (2001).
162. Springer G. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. (Berl.). 75(8), 594-602 (1997).
163. Springer GF, Desai PR, Tegtmeyer H, Carlstedt SC, Scanlon EF. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother. 9(1), 7-15 (1994).
164. Finn O. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3(8), 630-641 (2003).
165. Paula C, Motta A, Schmitz C et al. Alterations in dendritic cell function in aged mice: potential implications for immunotherapy design. Biogerontology 10(1), 13-25 (2009)
166. Ortiz R, Melguizo C, Prados J et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat. Anticancer Drug Discov. (2012) (Epub ahead of print).